BET and BRAF inhibitors act synergistically againstBRAF-mutant melanoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BET and BRAF inhibitors act synergistically againstBRAF-mutant melanoma
Authors
Keywords
-
Journal
Cancer Medicine
Volume 5, Issue 6, Pages 1183-1193
Publisher
Wiley
Online
2016-05-12
DOI
10.1002/cam4.667
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials
- (2015) Ruiqin Mai et al. Oncotarget
- Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus
- (2015) Holger Schipper et al. Oncotarget
- A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma
- (2014) Madhuri Bhandaru et al. BMC CANCER
- The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells
- (2014) Stuart J. Gallagher et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Systemic treatment for BRAF-mutant melanoma: where do we go next?
- (2014) Alexander M Menzies et al. LANCET ONCOLOGY
- Insulin-Like-Growth-Factor-Binding-Protein-3 (IGFBP-3) Contrasts Melanoma Progression In Vitro and In Vivo
- (2014) Antimo Naspi et al. PLoS One
- Control of Embryonic Stem Cell Identity by BRD4-Dependent Transcriptional Elongation of Super-Enhancer-Associated Pluripotency Genes
- (2014) Raffaella Di Micco et al. Cell Reports
- BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
- (2013) M. F. Segura et al. CANCER RESEARCH
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
- (2013) Scott R. Floyd et al. NATURE
- Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells
- (2013) D. Beck et al. Science Signaling
- Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma
- (2012) Christine Guo Lian et al. CELL
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress
- (2012) K Brooks et al. ONCOGENE
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- E2F1-dependent oncogenic addiction of melanoma cells to MDM2
- (2011) M Verhaegen et al. ONCOGENE
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- (2011) Mohammad Atefi et al. PLoS One
- Born to be Alive: A Role for the BCL-2 Family in Melanoma Tumor Cell Survival, Apoptosis, and Treatment
- (2011) Rina A. Anvekar et al. Frontiers in Oncology
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- (2010) H. Yang et al. CANCER RESEARCH
- Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
- (2010) L. Paoluzzi et al. CLINICAL CANCER RESEARCH
- The histone variant macroH2A suppresses melanoma progression through regulation of CDK8
- (2010) Avnish Kapoor et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
- (2008) L. Paoluzzi et al. BLOOD
- Bromodomain 4 activation predicts breast cancer survival
- (2008) N. P. S. Crawford et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More